Xilio Development Inc (XLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xilio Development Inc (XLO) has a cash flow conversion efficiency ratio of 2.161x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.50 Million) by net assets ($-8.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xilio Development Inc (XLO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Xilio Development Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Xilio Development Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xilio Development Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xilio Development Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cardlytics Inc
NASDAQ:CDLX
|
1.409x |
|
SOOSAN INT Co. Ltd
KQ:050960
|
0.012x |
|
dMY Squared Technology Group Inc
NYSE MKT:DMYY
|
1.695x |
|
Metallic Minerals Corp
V:MMG
|
-0.327x |
|
Ledlink Optics
TWO:5230
|
0.045x |
|
Speed Rabbit Pizza SA
PA:MLSRP
|
N/A |
|
Shriro Holdings Ltd
AU:SHM
|
0.205x |
|
Cyclone Metals Ltd
AU:CLE
|
-0.088x |
Annual Cash Flow Conversion Efficiency for Xilio Development Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Xilio Development Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Xilio Development Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.60 Million | $-18.38 Million | -1.044x | +43.95% |
| 2023-12-31 | $36.83 Million | $-68.62 Million | -1.863x | -159.96% |
| 2022-12-31 | $105.65 Million | $-75.72 Million | -0.717x | -64.59% |
| 2021-12-31 | $185.43 Million | $-80.75 Million | -0.435x | -106.38% |
| 2020-12-31 | $-5.29 Million | $-36.09 Million | 6.829x | +1573.87% |
| 2019-12-31 | $38.51 Million | $-17.84 Million | -0.463x | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which compr… Read more